Sentinel Lymph Node Biopsy in Locally Advanced Breast Cancer After Neoadjuvant Chemotherapy—an Indian Perspective
- 2 Downloads
Sentinel lymph node biopsy (SLNB) alone in early breast cancer is an established standard of care. However, the same results have not been replicated in locally advanced breast cancer (LABC) after neoadjuvant chemotherapy (NACT). We aim to examine the feasibility of SLNB in LABC patients post NACT to determine identification rates (IR) and false negative rates (FNR). This was a single tertiary cancer center–based prospective study from February 2017 to November 2018. Forty-four patients with LABC (T3, T4 with N0 or N1) were studied and response after NACT was assessed. Only those patients who were N0 or who converted from N1 to N0 after NACT were included. Those patients who remained node positive after NACT directly proceeded with axillary dissection without SLNB and were excluded from the study. Demographic and clinical data is expressed in ratios and percentage and presented in table format. The median age at the time of study was 45.18 years. Most of the patients had T3 and above (97.7%) and N1 (86.3%) disease at the start of neoadjuvant therapy. The mean number of axillary lymph nodes dissected was 13.97. Dual method of sentinel lymph node mapping (methylene blue dye and radiolabeled colloid) was used in 26 (59.1%) patients. At least 1 SLN was identified in 86.4% patients with 100% identification in those patients in whom the dual method of SLN mapping was used. Median of 2 SLN was removed. Overall, false negative rate was 21.4%. FNR was high with the single method of SLN mapping (50% and 33.3% with methylene blue and radioactive colloid respectively) while it was considerably low when both were used simultaneously (11%). An average of 2 (range 0–4) SLN were identified and FNR were zero when 2 or more SLN were identified. Our study shows that SLNB in patients with LABC post NACT though viable cannot be recommended at present due to unacceptable high FNR. However, this should not dissuade us from exploring recurrence-free survival and overall survival associated with such IR and FNR albeit strictly under a clinical trial setting.
KeywordsSentinel lymph node biopsy Locally advanced breast cancer Neoadjuvant chemotherapy Identification rate False negative rate
We would like to thank Dr. Durgesh Sahoo for his help in statistical assessment for the study.
Compliance with Ethical Standards
The study was approved by the Institution’s Scientific Review Board and Medical Ethics Committee (KMIO/MEC/007/24.Nov.2016).
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.Fisher B, Montague E, Redmond C, Barton B, Borland D, Fisher ER, Deutsch M, Schwarz G, Margolese R, Donegan W, Volk H, Konvolinka C, Gardner B, Cohn I Jr, Lesnick G, Cruz AB, Lawrence W, Nealon T, Butcher H, Lawton R (1977) Comparison of radical mastectomy with alternative treatments for primary breast cancer. A first report of results from a prospective randomized clinical trial. Cancer. 39:2827–2839CrossRefGoogle Scholar
- 2.Halsted WS (1898) I: a clinical and histological study of certain adenocarcinomata of the breast: and a brief consideration of the supraclavicular operation and of the results of operations for cancer of the breast from 1889 to 1898 at the Johns Hopkins Hospital. Ann Surg 28(5):557–576PubMedPubMedCentralGoogle Scholar
- 6.Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Wolmark N (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11(10):927–933. https://doi.org/10.1016/S1470-2045(10)70207-2 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O, Mastropasqua MG, Mazzarol G, Massarut S, Garbay JR, Zgajnar J, Galatius H, Recalcati A, Littlejohn D, Bamert M, Colleoni M, Price KN, Regan MM, Goldhirsch A, Coates AS, Gelber RD, Veronesi U, International Breast Cancer Study Group Trial 23-01 investigators (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 14(4):297–305. https://doi.org/10.1016/S1470-2045(13)70035-4 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall L, Morrow M (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6):569–575CrossRefGoogle Scholar
- 9.Classe JM, Loaec C, Gimbergues P, Alran S, de Lara CT, Dupre PF, Rouzier R, Faure C, Paillocher N, Chauvet MP, Houvenaeghel G, Gutowski M, De Blay P, Verhaeghe JL, Barranger E, Lefebvre C, Ngo C, Ferron G, Palpacuer C, Campion L (2018) Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-018-5004-7 CrossRefGoogle Scholar
- 10.Solá M, Alberro JA, Fraile M et al (2012) Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol 20:120–127. https://doi.org/10.1245/s10434-012-2569-y CrossRefPubMedGoogle Scholar
- 14.Yagata H, Yamauchi H, Tsugawa K, Hayashi N, Yoshida A, Kajiura Y, In R, Matsuda N, Nakamura S (2013 Dec) Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer. Clin Breast Cancer 13(6):471–477. https://doi.org/10.1016/j.clbc.2013.08.014 CrossRefPubMedGoogle Scholar
- 15.Haffty BG, McCall LM, Ballman KV, McLaughlin S, Jagsi R, Ollila DW, Hunt KK, Buchholz TA, Boughey JC (2016) Patterns of local-regional management following neoadjuvant chemotherapy in breast cancer: results from ACOSOG Z1071 Allia. Int J Radiat Oncol Biol Phys 94(3):493–502. https://doi.org/10.1016/j.ijrobp.2015.11.005 CrossRefPubMedGoogle Scholar
- 16.Chintamani TM, Mishra A, Agarwal U, Saxena S (2011) Sentinel lymph node biopsy using dye alone method is reliable and accurate even after neo-adjuvant chemotherapy in locally advanced breast cancer--a prospective study. World J Surg Oncol 9:19. https://doi.org/10.1186/1477-7819-9-19 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Parmar V, Hawaldar R, Nair NS, Shet T, Vanmali V, Desai S, Gupta S, Rangrajan V, Mittra I, Badwe RA (2013) Sentinel node biopsy versus low axillary sampling in women with clinically node negative operable breast cancer. Breast. 22(6):1081–1086. https://doi.org/10.1016/j.breast.2013.06.006 CrossRefPubMedGoogle Scholar
- 19.Shaitelman SF, Chiang YJ, Griffin KD, DeSnyder SM, Smith BD, Schaverien MV, Woodward WA, Cormier JN (2017) Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis. Breast Cancer Res Treat 162(2):201–215. https://doi.org/10.1007/s10549-016-4089-0 Review. Erratum in: Breast Cancer Res Treat. 2017 Apr;162(2):217CrossRefPubMedGoogle Scholar